Premium
Timed‐sequential high‐dose cyclophosphamide and vincristine in the treatment of multiple myeloma
Author(s) -
Lenhard Raymond E.,
Kalish Leslie A.,
Oken Martin M.,
Ettinger David S.,
Glick John
Publication year - 1994
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19940415)73:8<2113::aid-cncr2820730816>3.0.co;2-3
Subject(s) - medicine , vincristine , cyclophosphamide , multiple myeloma , oncology , cancer research , chemotherapy
Abstract Background. This study was designed to examine the efficacy and toxicity of high‐dose cyclophosphamide (CY), and to evaluate the potential added effect of vincristine (VCR) given at a theoretic time of malignant cell stimulation in a group of patients with multiple myeloma, refractory to or relapsing after, treatment with standard doses of chemotherapy. Methods. Patients were randomly assigned to receive CY 2400 mg per M 2 as a single‐day dose and VCR 1.4 mg per M 2 given on Day 1 or Day 9 after the CY. Results. There were 108 cases suitable for analysis. No difference in objective response (17.6%, 23.5%), subjective response, remission duration, or survival was observed in the two treatment arms. Conclusions. The authors conclude that a single, high dose of cyclophosphamide is more toxic and provides equal or less response than the equivalent dose given over 4 consecutive days and that no improved effect was detected using timed‐sequential therapy with VCR.